Author:Anoma Ranaweera B.V. Sc; PhD (Clinical Biochemistry, University of Liverpool, UK); Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, December 2014. Updated March 2018.
Pembrolizumab (trade name Keytruda®, formerly known as lambrolizumab) is a drug marketed by Merck and Co (New Jersey, USA) that targets the programmed death 1 (PD-1) receptor. The drug is intended for use in treating metastatic melanoma.
On September 4, 2014 the US Food and Drug Administration (FDA) approved pembrolizumab as a breakthrough therapy for the treatment of metastatic melanoma. It was approved for use in New Zealand in September 2015, and funded by PHARMAC for some patients with unresectable or metastatic melanoma from September 2016. Pembrolizumab is also used for metastatic non-small cell lung carcinoma, some cases of Hodgkin lymphoma, and urothelial carcinoma (March 2018). Pembrolizumab is under investigation in other malignancies. It has been reported to have some effect in metastatic Merkel cell carcinoma.
Pembrolizumab is indicated for the treatment of patients with unresectable or metastatic melanoma.
Combination therapy with other immunological drugs and targeted cancer therapy is under investigation and may improve response rates.
The programmed death receptor 1 (PD-1) is a surface molecule expressed on antigen-stimulated T-cells as well as monocytes, B-cells, and dendritic cells. In normal cells the PD-1 receptor acts as an immune checkpoint receptor enabling self-tolerance by T-cells, thus preventing autoimmune reactions.
When unbound, PD-1 allows the normal response by T-cells to proceed.
However, binding of PD-1 to its ligands, PD-L1 (programmed death receptor ligand 1) and PD-L2, suppresses the immune response by inducing downstream signalling that inhibits the proliferation of T-cells, cytokine release and cytotoxicity.
No formal pharmacokinetic drug interaction studies have been conducted with pembrolizumab.
In clinical trials, the most common side effects (greater than or equal to 20%) in patients receiving pembrolizumab 2 mg/kg every 3 weeks were:
The most frequent (greater than or equal to 2%) serious adverse drug reactions observed with pembrolizumab were renal failure, dyspnoea, pneumonia, and cellulitis. It can also cause infusion reactions including anaphylaxis.
Pembrolizumab also has the potential for severe immune-mediated adverse effects. In the 411 clinical trial participants with advanced melanoma, severe immune-mediated adverse effects included pneumonitis, colitis, hypophysitis, hyperthyroidism, hypothyroidism and other endocrinopathies, nephritis, and hepatitis. Other autoimmune diseases have subsequently been reported in association with pembrolizumab.
One report has described skin problems arising in 42% of 83 patients on pembrolizumab. Development of skin problems was associated with longer progression-free intervals. Case reports have described other skin problems during the post-marketing period.
Darkening of hair has been reported in a few patients taking PD-1 inhibitors for non-small cell lung cancer .
See the DermNet NZ bookstore.
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.